Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 8—August 2025

CME ACTIVITY - Synopsis

Emergence of Clade Ib Monkeypox Virus—Current State of Evidence

Panayampalli S. Satheshkumar1Comments to Author , Crystal M. Gigante1, Placide Mbala-Kingebeni, Yoshinori Nakazawa, Mark Anderson, Stephen Balinandi, Sophia Mulei, James Fuller, Jennifer H. McQuiston, Andrea M. McCollum, and Christina L. Hutson
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (P.S. Satheshkumar, C.M. Gigante, Y. Nakazawa, M. Anderson, J. Fuller, J.H. McQuiston, A.M. McCollum, C.L. Hutson); Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo (P. Mbala-Kingebeni); Uganda Virus Research Institute, Entebbe, Uganda (S. Balinandi, S. Mulei)

Main Article

Figure 3

Global distribution of laboratory-confirmed cases of clade I monkeypox virus according to subclade during January 1, 2024–April 27, 2025 (31). Size of circles indicates estimated number of cases.

Figure 3. Global distribution of laboratory-confirmed cases of clade I monkeypox virus according to subclade during January 1, 2024–April 27, 2025 (31). Size of circles indicates estimated number of cases.

Main Article

References
  1. World Health Organization. WHO Director-General’s statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox—23 July 2022. 2022 [cited 2025 May 9]. https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022
  2. World Health Organization. WHO Director-General declares mpox outbreak a public health emergency of international concern. 2024 [cited 2025 May 9]. https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern
  3. Beer  EM, Rao  VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019;13:e0007791. DOIPubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. 2022–2023 Mpox outbreak global map [cited 2025 May 9]. https://archive.cdc.gov/#/details?url=https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html
  5. Reynolds  MG, Wauquier  N, Li  Y, Satheshkumar  PS, Kanneh  LD, Monroe  B, et al. Human monkeypox in Sierra Leone after 44-year absence of reported cases. Emerg Infect Dis. 2019;25:1023–5. DOIPubMedGoogle Scholar
  6. Durski  KN, McCollum  AM, Nakazawa  Y, Petersen  BW, Reynolds  MG, Briand  S, et al. Emergence of Monkeypox - West and Central Africa, 1970-2017. MMWR Morb Mortal Wkly Rep. 2018;67:306–10. DOIPubMedGoogle Scholar
  7. Likos  AM, Sammons  SA, Olson  VA, Frace  AM, Li  Y, Olsen-Rasmussen  M, et al. A tale of two clades: monkeypox viruses. J Gen Virol. 2005;86:2661–72. DOIPubMedGoogle Scholar
  8. Curaudeau  M, Besombes  C, Nakouné  E, Fontanet  A, Gessain  A, Hassanin  A. Identifying the most probable mammal reservoir hosts for monkeypox virus based on ecological niche comparisons. Viruses. 2023;15:727. DOIPubMedGoogle Scholar
  9. Nakazawa  Y, Mauldin  MR, Emerson  GL, Reynolds  MG, Lash  RR, Gao  J, et al. A phylogeographic investigation of African monkeypox. Viruses. 2015;7:2168–84. DOIPubMedGoogle Scholar
  10. Yinka-Ogunleye  A, Aruna  O, Dalhat  M, Ogoina  D, McCollum  A, Disu  Y, et al.; CDC Monkeypox Outbreak Team. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19:872–9. DOIPubMedGoogle Scholar
  11. World Health Organization. 2022–24 Mpox (monkeypox) outbreak: global mpox trends. 2024 [cited 2025 May 9]. https://worldhealthorg.shinyapps.io/mpx_global/#21_Epidemic_curves
  12. Gigante  CM, Korber  B, Seabolt  MH, Wilkins  K, Davidson  W, Rao  AK, et al. Multiple lineages of monkeypox virus detected in the United States, 2021-2022. Science. 2022;378:560–5. DOIPubMedGoogle Scholar
  13. O’Toole  Á, Neher  RA, Ndodo  N, Borges  V, Gannon  B, Gomes  JP, et al. APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016. Science. 2023;382:595–600. DOIPubMedGoogle Scholar
  14. Isidro  J, Borges  V, Pinto  M, Sobral  D, Santos  JD, Nunes  A, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022;28:1569–72. DOIPubMedGoogle Scholar
  15. Suspène  R, Raymond  KA, Boutin  L, Guillier  S, Lemoine  F, Ferraris  O, et al. APOBEC3F is a mutational driver of the human monkeypox virus identified in the 2022 outbreak. J Infect Dis. 2023;228:1421–9. DOIPubMedGoogle Scholar
  16. Americo  JL, Earl  PL, Moss  B. Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model. Proc Natl Acad Sci U S A. 2023;120:e2220415120. DOIPubMedGoogle Scholar
  17. World Health Organization. Regional Office for Africa. Mpox in the WHO African Region. Weekly regional situation report #17. 2024 Dec 15 [cited 2025 May 9]. https://iris.who.int/handle/10665/379903/AFRO-Mpox%20bulletin-%2015%20December%202024.pdf
  18. European Centre for Disease Prevention and Control. Outbreak of mpox caused by monkeypox virus clade I in the Democratic Republic of the Congo. 2024 [cited 2025 May 9]. https://www.ecdc.europa.eu/en/news-events/outbreak-mpox-caused-monkeypox-virus-clade-i-democratic-republic-congo
  19. Vakaniaki  EH, Kacita  C, Kinganda-Lusamaki  E, O’Toole  Á, Wawina-Bokalanga  T, Mukadi-Bamuleka  D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med. 2024;30:2791–5. DOIPubMedGoogle Scholar
  20. Masirika  LM, Udahemuka  JC, Schuele  L, Ndishimye  P, Otani  S, Mbiribindi  JB, et al. Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the Congo, 2024. Euro Surveill. 2024;29:2400106. DOIPubMedGoogle Scholar
  21. McCollum  AM, Nakazawa  Y, Ndongala  GM, Pukuta  E, Karhemere  S, Lushima  RS, et al. Human monkeypox in the Kivus, a conflict region of the Democratic Republic of the Congo. Am J Trop Med Hyg. 2015;93:718–21. DOIPubMedGoogle Scholar
  22. Masirika  LM, Udahemuka  JC, Schuele  L, Nieuwenhuijse  DF, Ndishimye  P, Boter  M, et al. Epidemiological and genomic evolution of the ongoing outbreak of clade Ib mpox virus in the eastern Democratic Republic of the Congo. Nat Med. 2025;31:1459–63. DOIPubMedGoogle Scholar
  23. Wawina-Bokalanga  T, Akil-Bandali  P, Kinganda-Lusamaki  E, Lokilo  E, Jansen  D, Amuri-Aziza  A, et al. Co-circulation of monkeypox virus subclades Ia and Ib in Kinshasa Province, Democratic Republic of the Congo, July to August 2024. Euro Surveill. 2024;29:2400592. DOIPubMedGoogle Scholar
  24. Reed  KD, Melski  JW, Graham  MB, Regnery  RL, Sotir  MJ, Wegner  MV, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350:342–50. DOIPubMedGoogle Scholar
  25. Moss  B. Understanding the biology of monkeypox virus to prevent future outbreaks. Nat Microbiol. 2024;9:1408–16. DOIPubMedGoogle Scholar
  26. Bunge  EM, Hoet  B, Chen  L, Lienert  F, Weidenthaler  H, Baer  LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16:e0010141. DOIPubMedGoogle Scholar
  27. Government of the Democratic Republic of the Congo. Report on the epidemiological situation of monkeypox (Mpox) in the DRC—sitrep No 025 (29 August 2024) [cited 2025 May 9]. https://reliefweb.int/report/democratic-republic-congo/rapport-de-la-situation-epidemiologique-de-la-variole-simienne-mpox-en-rdc-sitrep-no-025-29-aout-2024
  28. Pittman  PR, Martin  JW, Kingebeni  PM, Tamfum  JM, Mwema  G, Wan  Q, et al.; Kole Human Mpox Infection Study Group. Clinical characterization and placental pathology of mpox infection in hospitalized patients in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2023;17:e0010384. DOIPubMedGoogle Scholar
  29. National Institutes of Health. The antiviral tecovirimat is safe but did not improve clade I mpox resolution in Democratic Republic of the Congo. 2024 [cited 2025 May 9]. https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo
  30. Brosius  I, Vakaniaki  EH, Mukari  G, Munganga  P, Tshomba  JC, De Vos  E, et al. Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study. Lancet. 2025;405:547–59. DOIPubMedGoogle Scholar
  31. World Health Organization. Global mpox trends. 2025 [cited 2025 May 9]. https://worldhealthorg.shinyapps.io/mpx_global/#severity
  32. Nizigiyimana  A, Ndikumwenayo  F, Houben  S, Manirakiza  M, van Lettow  M, Liesenborghs  L, et al. Epidemiological analysis of confirmed mpox cases, Burundi, 3 July to 9 September 2024. Euro Surveill. 2024;29:2400647. DOIPubMedGoogle Scholar
  33. Nzoyikorera  N, Nduwimana  C, Schuele  L, Nieuwenhuijse  DF, Koopmans  M, Otani  S, et al. Monkeypox Clade Ib virus introduction into Burundi: first findings, July to mid-August 2024. Euro Surveill. 2024;29:2400666. DOIPubMedGoogle Scholar
  34. Hudson  PN, Self  J, Weiss  S, Braden  Z, Xiao  Y, Girgis  NM, et al. Elucidating the role of the complement control protein in monkeypox pathogenicity. PLoS One. 2012;7:e35086. DOIPubMedGoogle Scholar
  35. Earl  PL, Americo  JL, Reynolds  S, Xiao  W, Cotter  C, Moss  B. A functional approach to analyze the genetic basis for differences in virulence of monkeypox virus clades. Emerg Microbes Infect. 2025;14:2456144. DOIPubMedGoogle Scholar
  36. Estep  RD, Messaoudi  I, O’Connor  MA, Li  H, Sprague  J, Barron  A, et al. Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol. 2011;85:9527–42. DOIPubMedGoogle Scholar
  37. Centers for Disease Control and Prevention. Prevention strategies for mpox, including vaccinating people at risk via sexual exposure, for U.S. travelers visiting countries with clade I mpox outbreaks. 2024 [cited 2025 May 9]. https://www.cdc.gov/han/2024/han00516.html
  38. Li  Y, Zhao  H, Wilkins  K, Hughes  C, Damon  IK. Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods. 2010;169:223–7. DOIPubMedGoogle Scholar
  39. Centers for Disease Control and Prevention. Non-variola orthopoxvirus generic real-time PCR test. 2022 [cited 2025 May 9]. https://www.cdc.gov/mpox/media/pdfs/2024/08/Non-variola-Orthopoxvirus-Generic-Real-Time-PCR-Test.pdf
  40. Li  Y, Olson  VA, Laue  T, Laker  MT, Damon  IK. Detection of monkeypox virus with real-time PCR assays. J Clin Virol. 2006;36:194–203. DOIPubMedGoogle Scholar
  41. Centers for Disease Control and Prevention. Mpox vaccine administration in the U.S. 2024 [cited 2025 May 9]. https://archive.cdc.gov/#/details?url=https://www.cdc.gov/poxvirus/mpox/response/2022/vaccines_data.html
  42. Guagliardo  SAJ, Kracalik  I, Carter  RJ, Braden  C, Free  R, Hamal  M, et al. Monkeypox virus infections after 2 preexposure doses of JYNNEOS vaccine—United States, May 2022–May 2024. MMWR Morb Mortal Wkly Rep. 2024;73:460–6. DOIPubMedGoogle Scholar
  43. Dalton  AF, Diallo  AO, Chard  AN, Moulia  DL, Deputy  NP, Fothergill  A, et al.; CDC Multijurisdictional Mpox Case Control Study Group. Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study—United States, August 19, 2022–March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:553–8. DOIPubMedGoogle Scholar
  44. Deputy  NP, Gerhart  JL, Feldstein  LR. Vaccine effectiveness against mpox in the United States. [Reply]. N Engl J Med. 2023;389:1440–1. DOIPubMedGoogle Scholar
  45. Wolff Sagy  Y, Zucker  R, Hammerman  A, Markovits  H, Arieh  NG, Abu Ahmad  W, et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023;29:748–52. DOIPubMedGoogle Scholar
  46. Rao  AK, Schrodt  CA, Minhaj  FS, Waltenburg  MA, Cash-Goldwasser  S, Yu  Y, et al. Interim clinical treatment considerations for severe manifestations of mpox—United States, February 2023. MMWR Morb Mortal Wkly Rep. 2023;72:232–43. DOIPubMedGoogle Scholar
  47. Garrigues  JM, Hemarajata  P, Espinosa  A, Hacker  JK, Wynn  NT, Smith  TG, et al. Community spread of a human monkeypox virus variant with a tecovirimat resistance-associated mutation. Antimicrob Agents Chemother. 2023;67:e0097223. DOIPubMedGoogle Scholar
  48. Smith  TG, Gigante  CM, Wynn  NT, Matheny  A, Davidson  W, Yang  Y, et al. Tecovirimat resistance in mpox patients, United States, 2022–2023. Emerg Infect Dis. 2023;29:2426–32. DOIPubMedGoogle Scholar
  49. Ali  R, Alonga  J, Biampata  JL, Kombozi Basika  M, Maljkovic Berry  I, Bisento  N, et al.; PALM007 Writing Group. Tecovirimat for clade I MPXV infection in the Democratic Republic of Congo. N Engl J Med. 2025;392:1484–96. DOIPubMedGoogle Scholar
  50. National Institutes of Health. NIH study finds tecovirimat was safe but did not improve mpox resolution or pain. 2024 [cited 2025 May 9]. https://www.nih.gov/news-events/news-releases/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain

Main Article

1These first authors contributed equally to the article.

Page created: May 19, 2025
Page updated: July 23, 2025
Page reviewed: July 23, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external